Completing data — refresh the page later to see the latest
Basic information
- CAS
185913-78-4- Standard SMILES
CCOc1ccc2c(c1)C1(CCC(OCCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC- InChIKey
QKXJWFOKVQWEDZ-UHFFFAOYSA-N- Molecular formula
- C33H45N3O8S
- Average molar mass
- 643.803 g/mol
- Monoisotopic mass
- 643.2927364
Names & identifiers
- Preferred name
- N-tert-Butyl-4-{5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-indole]-1'(2'H)-sulfonyl}-3-methoxybenzamide
- IUPAC
- N-tert-Butyl-4-{5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-indole]-1'(2'H)-sulfonyl}-3-methoxybenzamide
- English name
- satavaptan
- Molecular formula
- C33H45N3O8S
- Molecular weight
- 643.79
Names & synonyms
SR 121463satavaptanN-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamideBenzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-
Database identifiers
- CAS
185913-78-4- PubChem CID
- 158348
- DTXSID
DTXSID60870165- ChEMBL
CHEMBL4283439- ChEBI
CHEBI:194402- UNII
- AJS8S3P31H
- Nikkaji
- J1.012.840D
Properties
Physicochemical properties
- Density
- 1.31 · 1.31±0.1 g/cm3(Predicted)
- pka
- 14.04 · 14.04±0.46(Predicted)
- FDA UNII
- 8 S3P31H · AJS8S3P31H
- Symbol(GHS)
- 7 · GHS07,GHS08
- Signal word
- Warning
- Hazard statements
- 302 · H302-H361
- Precautionary statements
- 264 · P264-P270-P301+P312-P330-P501-P201-P202-P281-P308+P313-P405-P501
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07,GHS08
- Hazard statements
- H302-H361
- Precautionary statements
- P264-P270-P301+P312-P330-P501-P201-P202-P281-P308+P313-P405-P501
Chemistry & industry
Applications
UsesSatavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia[1].
Suppliers3 total
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
杭州洁汉化工有限公司+86-571-86217390; +8618058761490 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
Additional notes
DefinitionChEBI: Satavaptan is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. It has a role as a vasopressin receptor antagonist and an aquaretic. It is a member of morpholines, an aromatic ether, a member of benzamides, a secondary carboxamide, a monomethoxybenzene, a sulfonamide and an oxaspiro compound.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…